SCORE Search Results Details for Application 10571302 and Search Result 20081124_104456_us-10-571-302-1.rag.

This page gives you Search Results detail for the Application 10571302 and Search Result 20081124_104456_us-10-571-302-1.rag.

Go Back to previous page

GenCore version 6.3

OM protein - protein search, using sw model

Run on: November 24, 2008, 10:45:07 ; Search time 77 Seconds
(without alignments)
390.092 Million cell updates/sec

Title: US-10-571-302-1
Perfect score: 246
Sequence: 1 EDCIPKWKGCVNRHGDCCEGLECWKRRRSFEVCVPKTPKT 40

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 4151667 seqs, 751288301 residues

Total number of hits satisfying chosen parameters: 4151667

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_200808:*
1: geneseqp1980s:*
2: geneseqp1990s:*
3: geneseqp2000:*
4: geneseqp2001:*
5: geneseqp2002:*
6: geneseqp2003a:*
7: geneseqp2003b:*
8: geneseqp2004a:*

9: geneseqp2004b:*
10: geneseqp2005:*
11: geneseqp2006:*
12: geneseqp2007:*
13: geneseqp2008:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	246	100.0	40	5	AAU09425	Aau09425 Psalmopoe
2	246	100.0	40	10	ADY80805	Ady80805 Psalmotox
3	246	100.0	40	11	AEG95747	Aeg95747 Psalmotox
4	246	100.0	40	12	AFH53530	Afh53530 Tarantula
5	246	100.0	40	13	ARW11374	Arw11374 P. cambri
6	246	100.0	41	10	ADY80806	Ady80806 Psalmotox
7	235	95.5	38	11	AEG95748	Aeg95748 Psalmotox
8	235	95.5	38	12	AFH53531	Afh53531 Tarantula
9	235	95.5	38	13	ARW11375	Arw11375 P. cambri
10	229	93.1	37	11	AEG95749	Aeg95749 Psalmotox
11	229	93.1	37	12	AFH53532	Afh53532 Tarantula
12	229	93.1	37	13	ARW11376	Arw11376 P. cambri
13	208	84.6	33	11	AEG95750	Aeg95750 Psalmotox
14	208	84.6	33	12	AFH53533	Afh53533 Tarantula
15	208	84.6	33	13	ARW11377	Arw11377 P. cambri
16	197	80.1	31	11	AEG95751	Aeg95751 Psalmotox
17	197	80.1	31	12	AFH53534	Afh53534 Tarantula
18	197	80.1	31	13	ARW11378	Arw11378 P. cambri
19	67.5	27.4	54	10	AEA30177	Aea30177 Pertussis
20	67.5	27.4	58	10	AEA30251	Aea30251 Pertussis
21	67.5	27.4	62	10	AEA30306	Aea30306 Pertussis
22	66	26.8	54	10	AEA30264	Aea30264 Pertussis
23	66	26.8	62	10	AEA30305	Aea30305 Pertussis
24	65	26.4	35	5	AAO15120	Aao15120 Agriospho
25	65	26.4	54	10	AEA30174	Aea30174 Pertussis
26	65	26.4	60	10	AEA30248	Aea30248 Pertussis
27	65	26.4	62	10	AEA30293	Aea30293 Pertussis
28	64	26.0	35	10	AEA30163	Aea30163 Wild-type
29	64	26.0	36	5	AAO15121	Aao15121 Isyndus o
30	63	25.6	36	13	AOG35820	Aog35820 Antimicro
31	63	25.6	62	10	AEA30314	Aea30314 Pertussis
32	62.5	25.4	156	6	ADN40046	Adn40046 Cancer/an
33	62	25.2	51	10	AEA30303	Aea30303 Pertussis
34	62	25.2	54	10	AEA30175	Aea30175 Pertussis

35	62	25.2	60	10	AEA30249	Aea30249 Pertussis
36	62	25.2	62	10	AEA30297	Aea30297 Pertussis
37	61	24.8	34	10	AEA30222	Aea30222 Pertussis
38	61	24.8	34	10	AEA30160	Aea30160 Pertussis
39	61	24.8	54	10	AEA30285	Aea30285 Pertussis
40	61	24.8	54	10	AEA30190	Aea30190 Pertussis
41	60.5	24.6	31	2	AAR53578	Aar53578 Spider ve
42	60.5	24.6	31	2	AAR53574	Aar53574 Spider ve
43	60.5	24.6	31	2	AAR63752	Aar63752 Outward K
44	60.5	24.6	82	4	AAU06025	Aau06025 Cone snai
45	60.5	24.6	127	10	AEN25742	Aen25742 Solanum c

ALIGNMENTS

RESULT 1
AAU09425
ID AAU09425 standard; peptide; 40 AA.
XX
AC AAU09425;
XX
DT 15-JUN-2007 (revised)
DT 07-AUG-2003 (revised)
DT 12-MAR-2002 (first entry)
XX
DE Psalmopoeus cambridgei psalmotoxin 1 (PcTX1) polypeptide.
XX
KW Acid sensitive ion channel 1a blocker; ASIC1a channel blocker; PcTX1;
KW Psalmotoxin 1; South-American tarantula; proton-gated sodium channel;
KW venom.
XX
OS Unidentified.
XX
PN WO200185931-A2.
XX
PD 15-NOV-2001.
XX
PF 10-MAY-2001; 2001WO-IB000934.
XX
PR 10-MAY-2000; 2000US-0203309P.
PR 10-MAY-2001; 2001US-00852378.
XX
PA (CNRS) CNRS CENT NAT RECH SCI.
XX
PI Lazdunski M, Escoubas P, De Weille J, Diochot S;
XX
DR WPI; 2002-066602/09.
DR PC:NCBI; gi39654139.

```
XX
PT   Novel polypeptide functioning as acid sensitive ion channel 1a blocker,
PT   termed Psalmotoxin 1, isolated from venom of South-American tarantula
PT   Psalmopoeus carnbridgei.
XX
PS   Claim 6; Fig 1D; 32pp; English.
XX
CC   The present invention relates to a pure polypeptide functioning as an
CC   acid sensitive ion channel (ASIC) 1a blocker, called Psalmotoxin 1
CC   (PcTX1). The PcTX1 polypeptide is identified from the venom of the South-
CC   American tarantula Psalmopoeus cambridgei. The polypeptide of the
CC   invention is useful for inhibiting the proton-gated sodium channel,
CC   ASIC1a. A nucleic acid encoding the PcTX1 polypeptide is useful to
CC   transform animals and establish a line of transgenic animals, and as
CC   probes for hybridisation detection of similar polypeptides functioning as
CC   an ASIC1a channel blocker in other individuals or species and for PCR
CC   experiments, for example to search for genes in other species or with a
CC   diagnostic aim. A PcTX1 antibody is useful in the search for new
CC   polypeptides functioning as an ASIC1a channel blocker or its homologue in
CC   other species. The present sequence represents the C. cambridgei
CC   Psalmotoxin 1 (PcTX1) polypeptide of the invention. (Updated on 07-AUG-
CC   2003 to correct OS field.)
CC
CC   Revised record issued on 15-JUN-2007 : Enhanced with precomputed
CC   information from BOND.
XX
SQ   Sequence 40 AA;

  Query Match             100.0%;  Score 246;  DB 5;  Length 40;
  Best Local Similarity   100.0%;  Pred. No. 8.9e-22;
  Matches   40;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EDCIPKWKGCVNRHGDCCEGLECWKRRRSFEVCVPKTPKT 40
              |||||||||||||||||||||||||||||||||||||||
Db          1 EDCIPKWKGCVNRHGDCCEGLECWKRRRSFEVCVPKTPKT 40


RESULT 2
ADY80805
ID   ADY80805 standard; protein; 40 AA.
XX
AC   ADY80805;
XX
DT   15-JUN-2007  (revised)
DT   02-JUN-2005  (first entry)
XX
DE   Psalmotoxin 1 (PcTX1) SEQ ID NO 1.
XX
KW   cytostatic; gene therapy; pharmaceutical; cellular transport; glioma;
```

KW breast tumor; endocrine disease; gynecology and obstetrics; melanoma;
KW cancer; neoplasm; Psalmotoxin 1; PcTX1; BOND_PC; GO8200; GO9405; GO19871.
XX
OS Psalmopoeus cambridgei.
XX
PN WO2005025518-A2.
XX
PD 24-MAR-2005.
XX
PF 13-SEP-2004; 2004WO-US029970.
XX
PR 11-SEP-2003; 2003US-0502034P.
XX
PA (UABR-) UAB RES FOUND.
XX
PI Benos DJ, Bubien JK, Gillespie GY;
XX
DR WPI; 2005-233410/24.
DR PC:NCBI; gi44888346.
XX
PT Treatment of tumor in subject, where tumor has expression of sodium
PT channel mediating constitutive inward sodium current, involves
PT administering composition comprising PcTX1 or variant of PcTX1 linked to
PT cytotoxic agent.
XX
PS Claim 46; SEQ ID NO 1; 63pp; English.
XX
CC The invention describes a method of treating a tumor in a subject in need
CC of the treatment, where the tumor has an expression of a sodium channel
CC mediating a constitutive inward sodium current. The method involves
CC administering an amount of a pharmaceutical composition comprising PcTX1
CC (Psalmotoxin 1) or a variant of PcTX1 linked to a cytotoxic agent. Also
CC described are: diagnosis to identify individuals with tumors having a
CC constitutive inward Na + current; identifying agents that bind to a Na +
CC channel mediating a constitutive inward Na + current; identifying agents
CC that modulate a constitutive inward Na + current; and visualizing a tumor
CC in a subject in need of such visualization, where the tumor has an
CC expression of a Na + channel mediating a constitutive inward Na +
CC current. The method is useful for treating a tumor in a subject, where
CC the tumor has an expression of a Na + channel mediating a constitutive
CC inward Na + current. It is preferably useful for treating glioma, breast
CC carcinoma, or melanoma. This is the amino acid sequence of Psalmotoxin 1
CC (PcTX1) from the venom of the south american tarantula.
CC
CC Revised record issued on 15-JUN-2007 : Enhanced with precomputed
CC information from BOND.
XX
SQ Sequence 40 AA;

```
  Query Match             100.0%;  Score 246;  DB 10;  Length 40;
  Best Local Similarity   100.0%;  Pred. No. 8.9e-22;
  Matches   40;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EDCIPKWKGCVNRHGDCCEGLECWKRRRSFEVCVPKTPKT 40
              |||||||||||||||||||||||||||||||||||||||
Db          1 EDCIPKWKGCVNRHGDCCEGLECWKRRRSFEVCVPKTPKT 40


RESULT 3
AEG95747
ID   AEG95747 standard; peptide; 40 AA.
XX
AC   AEG95747;
XX
DT   15-JUN-2007  (revised)
DT   01-JUN-2006  (first entry)
XX
DE   Psalmotoxin 1 (PcTx1).
XX
KW   Acid sensing ion channel 1a inhibitor; psalmotoxin 1; PcTx1; ischemia;
KW   vasotropic; cardiovascular disease; drug screening; BOND_PC; GO8200;
KW   GO9405; GO19871.
XX
OS   Psalmopoeus cambridgei.
XX
PN   WO2006034035-A2.
XX
PD   30-MAR-2006.
XX
PF   16-SEP-2005; 2005WO-US033171.
XX
PR   16-SEP-2004; 2004US-0611241P.
XX
PA   (VIRO-) VIROGENOMICS INC.
XX
PI   Simon RP,  Xiong Z;
XX
DR   WPI; 2006-254090/26.
DR   PC:NCBI; gi44888346.
XX
PT   Treating ischemia comprises administering a therapeutically effective
PT   amount of acid sensing ion channel 1a inhibitor to an ischemic subject to
PT   reduce injury resulting from ischemia.
XX
PS   Claim 7; SEQ ID NO 1; 55pp; English.
XX
CC   The invention describes the treatment of ischemia which comprises
CC   administering a therapeutically effective amount of an acid sensing ion
```

```
CC   channel 1a (ASIC1a) inhibitor to an ischemic subject to reduce injury
CC   resulting from ischemia. Also included are: a method of identifying drugs
CC   for treating ischemia, comprising obtaining ASIC1a inhibitor(s), and
CC   testing the ASIC1a inhibitor(s) for effect on an ischemic subject; a
CC   composition for treatment of ischemia, comprising an ASIC1a inhibitor
CC   disposed in a vehicle at a concentration that provides a therapeutically
CC   effective amount of the ASlC1a inhibitor for treatment of ischemia when
CC   administered to an ischemic subject; a method of manufacturing a
CC   medicament for treatment of ischemia, comprising obtaining an ASIC1a
CC   inhibitor, and combining the ASIC1a inhibitor with a vehicle to produce a
CC   medicament having an inhibitor for administration to an ischemic subject
CC   for treatment of ischemia; and the use of an ASIC1a inhibitor for the
CC   manufacture of a medicament to treat ischemia. The step of administering
CC   includes a step of administering an ASIC1a inhibitor that inhibits ASIC1a
CC   selectively relative to other ASIC family member(s) and includes a step
CC   of administering a peptide that includes a cystine knot. It includes a
CC   step of administering a peptide that is identical to or a derivative of
CC   PcTx1 (SEQ ID NO:1; see AEG95747). The peptide is a derivative that
CC   differs from PcTx1 by at least one deletion, substitution, and/or
CC   addition of amino acid(s). A second inhibitor is administered to the
CC   subject, and configured to inhibit at least one other channel that is not
CC   a member of the acid sensing ion channel family. The step of screening
CC   includes a step of detecting calcium (Ca 2+ ) flux into the cultured
CC   cells. The step of detecting Ca 2+ flux is performed
CC   electrophysiologically, with a Ca 2+ sensitive dye, and/or with dye that
CC   is sensitive to membrane potential. The present sequence represents full-
CC   length psalmotoxin 1 (PcTx1).
CC
CC   Revised record issued on 15-JUN-2007 : Enhanced with precomputed
CC   information from BOND.
XX
SQ   Sequence 40 AA;

  Query Match             100.0%;  Score 246;  DB 11;  Length 40;
  Best Local Similarity   100.0%;  Pred. No. 8.9e-22;
  Matches   40;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EDCIPKWKGCVNRHGDCCEGLECWKRRRSFEVCVPKTPKT 40
              |||||||||||||||||||||||||||||||||||||||
Db          1 EDCIPKWKGCVNRHGDCCEGLECWKRRRSFEVCVPKTPKT 40


RESULT 4
AFH53530
ID   AFH53530 standard; protein; 40 AA.
XX
AC   AFH53530;
XX
DT   26-JUL-2007  (first entry)
```

XX

DE Tarantula psalmotoxin 1 PcTx.

XX

KW therapeutic; prophylaxis; neuron; nervous system injury; ischemia;
KW hypoxia; neuroprotective; vasotropic; psalmotoxin 1; PcTx;
KW Alzheimers disease; hypertension; epilepsy; brain injury;
KW cerebrovascular ischemia; nootropic; hypotensive; cerebroprotective;
KW anticonvulsant.

XX

OS Psalmopoeus cambridgei.

XX

PN WO2007030580-A2.

XX

PD 15-MAR-2007.

XX

PF 08-SEP-2006; 2006WO-US034796.

XX

PR 09-SEP-2005; 2005US-0715881P.
PR 19-MAY-2006; 2006US-0801830P.

XX

PA (UYOR-) UNIV OREGON HEALTH SCI.

XX

PI Stenzel-Poore M, Stevens S, Simon R;

XX

DR WPI; 2007-458051/44.

XX

PT Protecting a cell in a subject against excitotoxic injury, ischemia or
PT hypoxia by administering a composition comprising an agent that activates
PT a Toll-like receptor and a composition comprising an acid sensing ion
PT channel inhibitor.

XX

PS Disclosure; SEQ ID NO 6; 42pp; English.

XX

CC The invention describes a method of protecting a cell in a subject
CC against excitotoxic injury, ischemia or hypoxia by administering a
CC composition comprising an agent that activates a Toll-like receptor,
CC preferably a CpG oligonucleotide, and a composition comprising an acid
CC sensing ion channel (ASIC) inhibitor, preferably Tarantula psalmotoxin 1
CC (PcTx) or a related peptide. The invention also includes use of an ASIC
CC inhibitor in preparing a medicament for increasing the protective effect
CC of preconditioning treatment with an agent that binds to and activates a
CC Toll-like receptor. The ASIC inhibitor is useful in preparing a
CC medicament for increasing the protective effect of preconditioning
CC treatment with an agent that binds to and activates a Toll-like receptor,
CC where the preconditioning treatment protects against injury by an
CC excitotoxic event, an ischemic event and/or a hypoxic event. This
CC sequence is Tarantula psalmotoxin 1 PcTx.

XX

SQ Sequence 40 AA;

```
  Query Match             100.0%;  Score 246;  DB 12;  Length 40;
  Best Local Similarity   100.0%;  Pred. No. 8.9e-22;
  Matches   40;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EDCIPKWKGCVNRHGDCCEGLECWKRRRSFEVCVPKTPKT 40
              |||||||||||||||||||||||||||||||||||||||
Db          1 EDCIPKWKGCVNRHGDCCEGLECWKRRRSFEVCVPKTPKT 40


RESULT 5
ARW11374
ID   ARW11374 standard; protein; 40 AA.
XX
AC   ARW11374;
XX
DT   24-JUL-2008  (first entry)
XX
DE   P. cambridgei psalmotoxin 1 (PcTx1) fragment SEQ ID NO:1.
XX
KW   therapeutic; brain injury; cerebrovascular ischemia; acidosis; vulnerary;
KW   cerebroprotective; vasotropic; metabolic-gen.; PcTx1; psalmotoxin; toxin;
KW   BOND_PC; GO8200; GO9405; GO19871.
XX
OS   Psalmopoeus cambridgei.
XX
PN   WO2008063676-A2.
XX
PD   29-MAY-2008.
XX
PF   21-NOV-2007; 2007WO-US024436.
XX
PR   21-NOV-2006; 2006US-0860522P.
PR   20-NOV-2007; 2007US-00943546.
XX
PA   (NEUR-) NEUROPROTECT INC.
XX
PI   Simon RP,  Xiong Z;
XX
DR   WPI; 2008-G68865/42.
DR   PC:NCBI; gi44888346.
XX
PT   Preventing or treating brain injury caused by stroke or seizure in
PT   subject, involves administering inhibitor of acid sensing ion channel and
PT   secondary neuroprotective therapeutic agent.
XX
PS   Claim 10; SEQ ID NO 1; 120pp; English.
XX
CC   The invention relates to a method of preventing or treating brain injury
```

```
CC   caused by stroke, seizure or epilepsy in a subject. This is done by
CC   preventing acidosis by administering an inhibitor of acid sensing ion
CC   channel and a secondary neuroprotective therapeutic agent. The secondary
CC   neuroprotective therapeutic agent or any other adjunctive therapeutic
CC   agent that is an antagonist specific for a glutamate receptor,
CC   alkalinizing agent, anticoagulant, tissue plasminogen activator, asprin
CC   or an anti-platelet agent. The current sequence is that of a fragment of
CC   the P. cambridgei derived psalmotoxin PcTx1.
CC
CC   Revised record issued on 03-JUL-2008 : Enhanced with precomputed
CC   information from BOND.
XX
SQ   Sequence 40 AA;

  Query Match             100.0%;  Score 246;  DB 13;  Length 40;
  Best Local Similarity   100.0%;  Pred. No. 8.9e-22;
  Matches   40;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EDCIPKWKGCVNRHGDCCEGLECWKRRRSFEVCVPKTPKT 40
              ||||||||||||||||||||||||||||||||||||||||
Db          1 EDCIPKWKGCVNRHGDCCEGLECWKRRRSFEVCVPKTPKT 40


RESULT 6
ADY80806
ID   ADY80806 standard; protein; 41 AA.
XX
AC   ADY80806;
XX
DT   02-JUN-2005  (first entry)
XX
DE   Psalmotoxin 1 (PcTX1) SEQ ID NO 2.
XX
KW   cytostatic; gene therapy; pharmaceutical; cellular transport; glioma;
KW   breast tumor; endocrine disease; gynecology and obstetrics; melanoma;
KW   cancer; neoplasm; Psalmotoxin 1; PcTX1.
XX
OS   Psalmopoeus cambridgei.
XX
PN   WO2005025518-A2.
XX
PD   24-MAR-2005.
XX
PF   13-SEP-2004; 2004WO-US029970.
XX
PR   11-SEP-2003; 2003US-0502034P.
XX
PA   (UABR-) UAB RES FOUND.
XX
```

PI Benos DJ, Bubien JK, Gillespie GY;
XX
DR WPI; 2005-233410/24.
XX
PT Treatment of tumor in subject, where tumor has expression of sodium
PT channel mediating constitutive inward sodium current, involves
PT administering composition comprising PcTX1 or variant of PcTX1 linked to
PT cytotoxic agent.
XX
PS Claim 46; SEQ ID NO 2; 63pp; English.
XX
CC The invention describes a method of treating a tumor in a subject in need
CC of the treatment, where the tumor has an expression of a sodium channel
CC mediating a constitutive inward sodium current. The method involves
CC administering an amount of a pharmaceutical composition comprising PcTX1
CC (Psalmotoxin 1) or a variant of PcTX1 linked to a cytotoxic agent. Also
CC described are: diagnosis to identify individuals with tumors having a
CC constitutive inward Na + current; identifying agents that bind to a Na +
CC channel mediating a constitutive inward Na + current; identifying agents
CC that modulate a constitutive inward Na + current; and visualizing a tumor
CC in a subject in need of such visualization, where the tumor has an
CC expression of a Na + channel mediating a constitutive inward Na +
CC current. The method is useful for treating a tumor in a subject, where
CC the tumor has an expression of a Na + channel mediating a constitutive
CC inward Na + current. It is preferably useful for treating glioma, breast
CC carcinoma, or melanoma. This is the amino acid sequence of Psalmotoxin 1
CC (PcTX1) from the venom of the south american tarantula.
XX
SQ Sequence 41 AA;

Query Match 100.0%; Score 246; DB 10; Length 41;
Best Local Similarity 100.0%; Pred. No. 9.1e-22;
Matches 40; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 EDCIPKWKGCVNRHGDCCEGLECWKRRRSFEVCVPKTPKT 40
              |||||||||||||||||||||||||||||||||||||||||
Db          1 EDCIPKWKGCVNRHGDCCEGLECWKRRRSFEVCVPKTPKT 40
```

RESULT 7
AEG95748
ID AEG95748 standard; peptide; 38 AA.
XX
AC AEG95748;
XX
DT 01-JUN-2006 (first entry)
XX
DE Psalmotoxin 1 (PcTx1), N-terminal deletion SEQ ID NO:2.
XX

KW Acid sensing ion channel 1a inhibitor; psalmotoxin 1; PcTx1; ischemia;
KW vasotropic; cardiovascular disease; drug screening.
XX
OS Psalmopoeus cambridgei.
OS Synthetic.
XX
PN WO2006034035-A2.
XX
PD 30-MAR-2006.
XX
PF 16-SEP-2005; 2005WO-US033171.
XX
PR 16-SEP-2004; 2004US-0611241P.
XX
PA (VIRO-) VIROGENOMICS INC.
XX
PI Simon RP, Xiong Z;
XX
DR WPI; 2006-254090/26.
XX
PT Treating ischemia comprises administering a therapeutically effective
PT amount of acid sensing ion channel 1a inhibitor to an ischemic subject to
PT reduce injury resulting from ischemia.
XX
PS Example 2; SEQ ID NO 2; 55pp; English.
XX
CC The invention describes the treatment of ischemia which comprises
CC administering a therapeutically effective amount of an acid sensing ion
CC channel 1a (ASIC1a) inhibitor to an ischemic subject to reduce injury
CC resulting from ischemia. Also included are: a method of identifying drugs
CC for treating ischemia, comprising obtaining ASIC1a inhibitor(s), and
CC testing the ASIC1a inhibitor(s) for effect on an ischemic subject; a
CC composition for treatment of ischemia, comprising an ASIC1a inhibitor
CC disposed in a vehicle at a concentration that provides a therapeutically
CC effective amount of the AS1C1a inhibitor for treatment of ischemia when
CC administered to an ischemic subject; a method of manufacturing a
CC medicament for treatment of ischemia, comprising obtaining an ASIC1a
CC inhibitor, and combining the ASIC1a inhibitor with a vehicle to produce a
CC medicament having an inhibitor for administration to an ischemic subject
CC for treatment of ischemia; and the use of an ASIC1a inhibitor for the
CC manufacture of a medicament to treat ischemia. The step of administering
CC includes a step of administering an ASIC1a inhibitor that inhibits ASIC1a
CC selectively relative to other ASIC family member(s) and includes a step
CC of administering a peptide that includes a cystine knot. It includes a
CC step of administering a peptide that is identical to or a derivative of
CC PcTx1 (SEQ ID NO:1; see AEG95747). The peptide is a derivative that
CC differs from PcTx1 by at least one deletion, substitution, and/or
CC addition of amino acid(s). A second inhibitor is administered to the
CC subject, and configured to inhibit at least one other channel that is not

CC a member of the acid sensing ion channel family. The step of screening
CC includes a step of detecting calcium (Ca 2+) flux into the cultured
CC cells. The step of detecting Ca 2+ flux is performed
CC electrophysiologically, with a Ca 2+ sensitive dye, and/or with dye that
CC is sensitive to membrane potential. The present sequence represents full-
CC length psalmotoxin 1 (PcTx1), N-terminal deletion SEQ ID NO:2.
XX
SQ Sequence 38 AA;

Query Match 95.5%; Score 235; DB 11; Length 38;
Best Local Similarity 100.0%; Pred. No. 1.7e-20;
Matches 38; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          3 CIPKWKGCVNRHGDCCEGLECWKRRRSFEVCVPKTPKT 40
              |||||||||||||||||||||||||||||||||||||||
Db          1 CIPKWKGCVNRHGDCCEGLECWKRRRSFEVCVPKTPKT 38
```

RESULT 8
AFH53531
ID AFH53531 standard; peptide; 38 AA.
XX
AC AFH53531;
XX
DT 26-JUL-2007 (first entry)
XX
DE Tarantula psalmotoxin 1 PcTx peptide SEQ ID NO:7.
XX
KW therapeutic; prophylaxis; neuron; nervous system injury; ischemia;
KW hypoxia; neuroprotective; vasotropic; psalmotoxin 1; PcTx;
KW Alzheimers disease; hypertension; epilepsy; brain injury;
KW cerebrovascular ischemia; nootropic; hypotensive; cerebroprotective;
KW anticonvulsant.
XX
OS Psalmopoeus cambridgei.
XX
PN WO2007030580-A2.
XX
PD 15-MAR-2007.
XX
PF 08-SEP-2006; 2006WO-US034796.
XX
PR 09-SEP-2005; 2005US-0715881P.
PR 19-MAY-2006; 2006US-0801830P.
XX
PA (UYOR-) UNIV OREGON HEALTH SCI.
XX
PI Stenzel-Poore M, Stevens S, Simon R;
XX

DR WPI; 2007-458051/44.
XX
PT Protecting a cell in a subject against excitotoxic injury, ischemia or
PT hypoxia by administering a composition comprising an agent that activates
PT a Toll-like receptor and a composition comprising an acid sensing ion
PT channel inhibitor.
XX
PS Disclosure; SEQ ID NO 7; 42pp; English.
XX
CC The invention describes a method of protecting a cell in a subject
CC against excitotoxic injury, ischemia or hypoxia by administering a
CC composition comprising an agent that activates a Toll-like receptor,
CC preferably a CpG oligonucleotide, and a composition comprising an acid
CC sensing ion channel (ASIC) inhibitor, preferably Tarantula psalmotoxin 1
CC (PcTx) or a related peptide. The invention also includes use of an ASIC
CC inhibitor in preparing a medicament for increasing the protective effect
CC of preconditioning treatment with an agent that binds to and activates a
CC Toll-like receptor. The ASIC inhibitor is useful in preparing a
CC medicament for increasing the protective effect of preconditioning
CC treatment with an agent that binds to and activates a Toll-like receptor,
CC where the preconditioning treatment protects against injury by an
CC excitotoxic event, an ischemic event and/or a hypoxic event. This
CC sequence is a Tarantula psalmotoxin 1 PcTx-derived peptide.
XX
SQ Sequence 38 AA;

Query Match 95.5%; Score 235; DB 12; Length 38;
Best Local Similarity 100.0%; Pred. No. 1.7e-20;
Matches 38; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          3 CIPKWKGCVNRHGDCCEGLECWKRRRSFEVCVPKTPKT 40
              |||||||||||||||||||||||||||||||||||||||
Db          1 CIPKWKGCVNRHGDCCEGLECWKRRRSFEVCVPKTPKT 38
```

RESULT 9
ARW11375
ID ARW11375 standard; peptide; 38 AA.
XX
AC ARW11375;
XX
DT 24-JUL-2008 (first entry)
XX
DE P. cambridgei psalmotoxin 1 (PcTx1) deletion variant SEQ ID NO:2.
XX
KW therapeutic; brain injury; cerebrovascular ischemia; acidosis; vulnerary;
KW cerebroprotective; vasotropic; metabolic-gen.; PcTx1; psalmotoxin; toxin.
XX
OS Psalmopoeus cambridgei.

XX
PN WO2008063676-A2.
XX
PD 29-MAY-2008.
XX
PF 21-NOV-2007; 2007WO-US024436.
XX
PR 21-NOV-2006; 2006US-0860522P.
PR 20-NOV-2007; 2007US-00943546.
XX
PA (NEUR-) NEUROPROTECT INC.
XX
PI Simon RP, Xiong Z;
XX
DR WPI; 2008-G68865/42.
XX
PT Preventing or treating brain injury caused by stroke or seizure in
PT subject, involves administering inhibitor of acid sensing ion channel and
PT secondary neuroprotective therapeutic agent.
XX
PS Claim 11; SEQ ID NO 2; 120pp; English.
XX
CC The invention relates to a method of preventing or treating brain injury
CC caused by stroke, seizure or epilepsy in a subject. This is done by
CC preventing acidosis by administering an inhibitor of acid sensing ion
CC channel and a secondary neuroprotective therapeutic agent. The secondary
CC neuroprotective therapeutic agent or any other adjunctive therapeutic
CC agent that is an antagonist specific for a glutamate receptor,
CC alkalinizing agent, anticoagulant, tissue plasminogen activator, asprin
CC or an anti-platelet agent. The current sequence is that of a deletion
CC variant of the P. cambridgei derived psalmotoxin PcTx1 with a 70 amino
CC acid N-terminal deletion.
XX
SQ Sequence 38 AA;

Query Match 95.5%; Score 235; DB 13; Length 38;
Best Local Similarity 100.0%; Pred. No. 1.7e-20;
Matches 38; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 CIPKWKGCVNRHGDCCEGLECWKRRRSFEVCVPKTPKT 40
||||||||||||||||||||||||||||||||||||||||
Db 1 CIPKWKGCVNRHGDCCEGLECWKRRRSFEVCVPKTPKT 38

RESULT 10
AEG95749
ID AEG95749 standard; peptide; 37 AA.
XX
AC AEG95749;

XX
DT 01-JUN-2006 (first entry)
XX
DE Psalmotoxin 1 (PcTx1), C-terminal deletion SEQ ID NO:3.
XX
KW Acid sensing ion channel 1a inhibitor; psalmotoxin 1; PcTx1; ischemia;
KW vasotropic; cardiovascular disease; drug screening.
XX
OS Psalmopoeus cambridgei.
OS Synthetic.
XX
PN WO2006034035-A2.
XX
PD 30-MAR-2006.
XX
PF 16-SEP-2005; 2005WO-US033171.
XX
PR 16-SEP-2004; 2004US-0611241P.
XX
PA (VIRO-) VIROGENOMICS INC.
XX
PI Simon RP, Xiong Z;
XX
DR WPI; 2006-254090/26.
XX
PT Treating ischemia comprises administering a therapeutically effective
PT amount of acid sensing ion channel 1a inhibitor to an ischemic subject to
PT reduce injury resulting from ischemia.
XX
PS Example 2; SEQ ID NO 3; 55pp; English.
XX
CC The invention describes the treatment of ischemia which comprises
CC administering a therapeutically effective amount of an acid sensing ion
CC channel 1a (ASIC1a) inhibitor to an ischemic subject to reduce injury
CC resulting from ischemia. Also included are: a method of identifying drugs
CC for treating ischemia, comprising obtaining ASIC1a inhibitor(s), and
CC testing the ASIC1a inhibitor(s) for effect on an ischemic subject; a
CC composition for treatment of ischemia, comprising an ASIC1a inhibitor
CC disposed in a vehicle at a concentration that provides a therapeutically
CC effective amount of the ASlC1a inhibitor for treatment of ischemia when
CC administered to an ischemic subject; a method of manufacturing a
CC medicament for treatment of ischemia, comprising obtaining an ASIC1a
CC inhibitor, and combining the ASIC1a inhibitor with a vehicle to produce a
CC medicament having an inhibitor for administration to an ischemic subject
CC for treatment of ischemia; and the use of an ASIC1a inhibitor for the
CC manufacture of a medicament to treat ischemia. The step of administering
CC includes a step of administering an ASIC1a inhibitor that inhibits ASIC1a
CC selectively relative to other ASIC family member(s) and includes a step
CC of administering a peptide that includes a cystine knot. It includes a

```
CC   step of administering a peptide that is identical to or a derivative of
CC   PcTx1 (SEQ ID NO:1; see AEG95747). The peptide is a derivative that
CC   differs from PcTx1 by at least one deletion, substitution, and/or
CC   addition of amino acid(s). A second inhibitor is administered to the
CC   subject, and configured to inhibit at least one other channel that is not
CC   a member of the acid sensing ion channel family. The step of screening
CC   includes a step of detecting calcium (Ca 2+ ) flux into the cultured
CC   cells. The step of detecting Ca 2+ flux is performed
CC   electrophysiologically, with a Ca 2+ sensitive dye, and/or with dye that
CC   is sensitive to membrane potential. The present sequence represents full-
CC   length psalmotoxin 1 (PcTx1), C-terminal deletion SEQ ID NO:3.
XX
SQ   Sequence 37 AA;

  Query Match             93.1%;  Score 229;  DB 11;  Length 37;
  Best Local Similarity   100.0%;  Pred. No. 8.8e-20;
  Matches   37;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EDCIPKWKGCVNRHGDCCEGLECWKRRRSFEVCVPKT 37
              |||||||||||||||||||||||||||||||||||||
Db          1 EDCIPKWKGCVNRHGDCCEGLECWKRRRSFEVCVPKT 37


RESULT 11
AFH53532
ID   AFH53532 standard; peptide; 37 AA.
XX
AC   AFH53532;
XX
DT   26-JUL-2007  (first entry)
XX
DE   Tarantula psalmotoxin 1 PcTx peptide SEQ ID NO:8.
XX
KW   therapeutic; prophylaxis; neuron; nervous system injury; ischemia;
KW   hypoxia; neuroprotective; vasotropic; psalmotoxin 1; PcTx;
KW   Alzheimers disease; hypertension; epilepsy; brain injury;
KW   cerebrovascular ischemia; nootropic; hypotensive; cerebroprotective;
KW   anticonvulsant.
XX
OS   Psalmopoeus cambridgei.
XX
PN   WO2007030580-A2.
XX
PD   15-MAR-2007.
XX
PF   08-SEP-2006; 2006WO-US034796.
XX
PR   09-SEP-2005; 2005US-0715881P.
PR   19-MAY-2006; 2006US-0801830P.
```

XX
PA (UYOR-) UNIV OREGON HEALTH SCI.
XX
PI Stenzel-Poore M, Stevens S, Simon R;
XX
DR WPI; 2007-458051/44.
XX
PT Protecting a cell in a subject against excitotoxic injury, ischemia or
PT hypoxia by administering a composition comprising an agent that activates
PT a Toll-like receptor and a composition comprising an acid sensing ion
PT channel inhibitor.
XX
PS Disclosure; SEQ ID NO 8; 42pp; English.
XX
CC The invention describes a method of protecting a cell in a subject
CC against excitotoxic injury, ischemia or hypoxia by administering a
CC composition comprising an agent that activates a Toll-like receptor,
CC preferably a CpG oligonucleotide, and a composition comprising an acid
CC sensing ion channel (ASIC) inhibitor, preferably Tarantula psalmotoxin 1
CC (PcTx) or a related peptide. The invention also includes use of an ASIC
CC inhibitor in preparing a medicament for increasing the protective effect
CC of preconditioning treatment with an agent that binds to and activates a
CC Toll-like receptor. The ASIC inhibitor is useful in preparing a
CC medicament for increasing the protective effect of preconditioning
CC treatment with an agent that binds to and activates a Toll-like receptor,
CC where the preconditioning treatment protects against injury by an
CC excitotoxic event, an ischemic event and/or a hypoxic event. This
CC sequence is a Tarantula psalmotoxin 1 PcTx-derived peptide.
XX
SQ Sequence 37 AA;

Query Match 93.1%; Score 229; DB 12; Length 37;
Best Local Similarity 100.0%; Pred. No. 8.8e-20;
Matches 37; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EDCIPKWKGCVNRHGDCCEGLECWKRRRSFEVCVPKT 37
||||||||||||||||||||||||||||||||||||||
Db 1 EDCIPKWKGCVNRHGDCCEGLECWKRRRSFEVCVPKT 37

RESULT 12
ARW11376
ID ARW11376 standard; peptide; 37 AA.
XX
AC ARW11376;
XX
DT 24-JUL-2008 (first entry)
XX
DE P. cambridgei psalmotoxin 1 (PcTx1) deletion variant SEQ ID NO:3.

XX
KW therapeutic; brain injury; cerebrovascular ischemia; acidosis; vulnerary;
KW cerebroprotective; vasotropic; metabolic-gen.; PcTx1; psalmotoxin; toxin.
XX
OS Psalmopoeus cambridgei.
XX
PN WO2008063676-A2.
XX
PD 29-MAY-2008.
XX
PF 21-NOV-2007; 2007WO-US024436.
XX
PR 21-NOV-2006; 2006US-0860522P.
PR 20-NOV-2007; 2007US-00943546.
XX
PA (NEUR-) NEUROPROTECT INC.
XX
PI Simon RP, Xiong Z;
XX
DR WPI; 2008-G68865/42.
XX
PT Preventing or treating brain injury caused by stroke or seizure in
PT subject, involves administering inhibitor of acid sensing ion channel and
PT secondary neuroprotective therapeutic agent.
XX
PS Claim 12; SEQ ID NO 3; 120pp; English.
XX
CC The invention relates to a method of preventing or treating brain injury
CC caused by stroke, seizure or epilepsy in a subject. This is done by
CC preventing acidosis by administering an inhibitor of acid sensing ion
CC channel and a secondary neuroprotective therapeutic agent. The secondary
CC neuroprotective therapeutic agent or any other adjunctive therapeutic
CC agent that is an antagonist specific for a glutamate receptor,
CC alkalinizing agent, anticoagulant, tissue plasminogen activator, asprin
CC or an anti-platelet agent. The current sequence is that of a deletion
CC variant of the P. cambridgei derived psalmotoxin PcTx1 with a 72 amino
CC acid C-terminal deletion.
XX
SQ Sequence 37 AA;

Query Match 93.1%; Score 229; DB 13; Length 37;
Best Local Similarity 100.0%; Pred. No. 8.8e-20;
Matches 37; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EDCIPKWKGCVNRHGDCCEGLECWKRRRSFEVCVPKT 37
||||||||||||||||||||||||||||||||||||||
Db 1 EDCIPKWKGCVNRHGDCCEGLECWKRRRSFEVCVPKT 37

```
RESULT 13
AEG95750
ID   AEG95750 standard; peptide; 33 AA.
XX
AC   AEG95750;
XX
DT   01-JUN-2006  (first entry)
XX
DE   Psalmotoxin 1 (PcTx1), C-terminal deletion SEQ ID NO:4.
XX
KW   Acid sensing ion channel 1a inhibitor; psalmotoxin 1; PcTx1; ischemia;
KW   vasotropic; cardiovascular disease; drug screening.
XX
OS   Psalmopoeus cambridgei.
OS   Synthetic.
XX
PN   WO2006034035-A2.
XX
PD   30-MAR-2006.
XX
PF   16-SEP-2005; 2005WO-US033171.
XX
PR   16-SEP-2004; 2004US-0611241P.
XX
PA   (VIRO-) VIROGENOMICS INC.
XX
PI   Simon RP,  Xiong Z;
XX
DR   WPI; 2006-254090/26.
XX
PT   Treating ischemia comprises administering a therapeutically effective
PT   amount of acid sensing ion channel 1a inhibitor to an ischemic subject to
PT   reduce injury resulting from ischemia.
XX
PS   Example 2; SEQ ID NO 4; 55pp; English.
XX
CC   The invention describes the treatment of ischemia which comprises
CC   administering a therapeutically effective amount of an acid sensing ion
CC   channel 1a (ASIC1a) inhibitor to an ischemic subject to reduce injury
CC   resulting from ischemia. Also included are: a method of identifying drugs
CC   for treating ischemia, comprising obtaining ASIC1a inhibitor(s), and
CC   testing the ASIC1a inhibitor(s) for effect on an ischemic subject; a
CC   composition for treatment of ischemia, comprising an ASIC1a inhibitor
CC   disposed in a vehicle at a concentration that provides a therapeutically
CC   effective amount of the ASlC1a inhibitor for treatment of ischemia when
CC   administered to an ischemic subject; a method of manufacturing a
CC   medicament for treatment of ischemia, comprising obtaining an ASIC1a
CC   inhibitor, and combining the ASIC1a inhibitor with a vehicle to produce a
CC   medicament having an inhibitor for administration to an ischemic subject
```

CC for treatment of ischemia; and the use of an ASIC1a inhibitor for the
CC manufacture of a medicament to treat ischemia. The step of administering
CC includes a step of administering an ASIC1a inhibitor that inhibits ASIC1a
CC selectively relative to other ASIC family member(s) and includes a step
CC of administering a peptide that includes a cystine knot. It includes a
CC step of administering a peptide that is identical to or a derivative of
CC PcTx1 (SEQ ID NO:1; see AEG95747). The peptide is a derivative that
CC differs from PcTx1 by at least one deletion, substitution, and/or
CC addition of amino acid(s). A second inhibitor is administered to the
CC subject, and configured to inhibit at least one other channel that is not
CC a member of the acid sensing ion channel family. The step of screening
CC includes a step of detecting calcium (Ca 2+) flux into the cultured
CC cells. The step of detecting Ca 2+ flux is performed
CC electrophysiologically, with a Ca 2+ sensitive dye, and/or with dye that
CC is sensitive to membrane potential. The present sequence represents full-
CC length psalmotoxin 1 (PcTx1), C-terminal deletion SEQ ID NO:4.
XX
SQ Sequence 33 AA;

Query Match 84.6%; Score 208; DB 11; Length 33;
Best Local Similarity 100.0%; Pred. No. 2.5e-17;
Matches 33; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 EDCIPKWKGCVNRHGDCCEGLECWKRRRSFEVC 33
              |||||||||||||||||||||||||||||||||
Db          1 EDCIPKWKGCVNRHGDCCEGLECWKRRRSFEVC 33
```

RESULT 14
AFH53533
ID AFH53533 standard; peptide; 33 AA.
XX
AC AFH53533;
XX
DT 26-JUL-2007 (first entry)
XX
DE Tarantula psalmotoxin 1 PcTx peptide SEQ ID NO:9.
XX
KW therapeutic; prophylaxis; neuron; nervous system injury; ischemia;
KW hypoxia; neuroprotective; vasotropic; psalmotoxin 1; PcTx;
KW Alzheimers disease; hypertension; epilepsy; brain injury;
KW cerebrovascular ischemia; nootropic; hypotensive; cerebroprotective;
KW anticonvulsant.
XX
OS Psalmopoeus cambridgei.
XX
PN WO2007030580-A2.
XX
PD 15-MAR-2007.

XX
PF 08-SEP-2006; 2006WO-US034796.
XX
PR 09-SEP-2005; 2005US-0715881P.
PR 19-MAY-2006; 2006US-0801830P.
XX
PA (UYOR-) UNIV OREGON HEALTH SCI.
XX
PI Stenzel-Poore M, Stevens S, Simon R;
XX
DR WPI; 2007-458051/44.
XX
PT Protecting a cell in a subject against excitotoxic injury, ischemia or
PT hypoxia by administering a composition comprising an agent that activates
PT a Toll-like receptor and a composition comprising an acid sensing ion
PT channel inhibitor.
XX
PS Disclosure; SEQ ID NO 9; 42pp; English.
XX
CC The invention describes a method of protecting a cell in a subject
CC against excitotoxic injury, ischemia or hypoxia by administering a
CC composition comprising an agent that activates a Toll-like receptor,
CC preferably a CpG oligonucleotide, and a composition comprising an acid
CC sensing ion channel (ASIC) inhibitor, preferably Tarantula psalmotoxin 1
CC (PcTx) or a related peptide. The invention also includes use of an ASIC
CC inhibitor in preparing a medicament for increasing the protective effect
CC of preconditioning treatment with an agent that binds to and activates a
CC Toll-like receptor. The ASIC inhibitor is useful in preparing a
CC medicament for increasing the protective effect of preconditioning
CC treatment with an agent that binds to and activates a Toll-like receptor,
CC where the preconditioning treatment protects against injury by an
CC excitotoxic event, an ischemic event and/or a hypoxic event. This
CC sequence is a Tarantula psalmotoxin 1 PcTx-derived peptide.
XX
SQ Sequence 33 AA;

Query Match 84.6%; Score 208; DB 12; Length 33;
Best Local Similarity 100.0%; Pred. No. 2.5e-17;
Matches 33; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 EDCIPKWKGCVNRHGDCCEGLECWKRRRSFEVC 33
              |||||||||||||||||||||||||||||||||
Db          1 EDCIPKWKGCVNRHGDCCEGLECWKRRRSFEVC 33
```

RESULT 15
ARW11377
ID ARW11377 standard; peptide; 33 AA.
XX

AC ARW11377;
XX
DT 24-JUL-2008 (first entry)
XX
DE P. cambridgei psalmotoxin 1 (PcTx1) deletion variant SEQ ID NO:4.
XX
KW therapeutic; brain injury; cerebrovascular ischemia; acidosis; vulnerary;
KW cerebroprotective; vasotropic; metabolic-gen.; PcTx1; psalmotoxin; toxin.
XX
OS Psalmopoeus cambridgei.
XX
PN WO2008063676-A2.
XX
PD 29-MAY-2008.
XX
PF 21-NOV-2007; 2007WO-US024436.
XX
PR 21-NOV-2006; 2006US-0860522P.
PR 20-NOV-2007; 2007US-00943546.
XX
PA (NEUR-) NEUROPROTECT INC.
XX
PI Simon RP, Xiong Z;
XX
DR WPI; 2008-G68865/42.
XX
PT Preventing or treating brain injury caused by stroke or seizure in
PT subject, involves administering inhibitor of acid sensing ion channel and
PT secondary neuroprotective therapeutic agent.
XX
PS Claim 13; SEQ ID NO 4; 120pp; English.
XX
CC The invention relates to a method of preventing or treating brain injury
CC caused by stroke, seizure or epilepsy in a subject. This is done by
CC preventing acidosis by administering an inhibitor of acid sensing ion
CC channel and a secondary neuroprotective therapeutic agent. The secondary
CC neuroprotective therapeutic agent or any other adjunctive therapeutic
CC agent that is an antagonist specific for a glutamate receptor,
CC alkalinizing agent, anticoagulant, tissue plasminogen activator, asprin
CC or an anti-platelet agent. The current sequence is that of a deletion
CC variant of the P. cambridgei derived psalmotoxin PcTx1 with a 74 amino
CC acid C-terminal deletion.
XX
SQ Sequence 33 AA;

Query Match 84.6%; Score 208; DB 13; Length 33;
Best Local Similarity 100.0%; Pred. No. 2.5e-17;
Matches 33; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 EDCIPKWKGCVNRHGDCCEGLECWKRRRSFEVC 33
              ||||||||||||||||||||||||||||||||||
Db          1 EDCIPKWKGCVNRHGDCCEGLECWKRRRSFEVC 33


Search completed: November 24, 2008, 10:47:45
Job time : 78.037 secs
```

SCORE 3.0